Document:

Exhibit 10.2

 

Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. The omissions have been indicated by “[**Redacted**]”, and the omitted text has been filed separately with the Securities and Exchange Commission.

 

SIXTH AMENDMENT TO SUPPLY AGREEMENT

 

This Sixth Amendment to the Supply Agreement (the “Sixth Amendment”) is entered into the 1st day of October, 2012, by and between Rite Aid Corporation (“Rite Aid”) and McKesson Corporation (“McKesson”).

 

INTRODUCTION

 

Pursuant to the terms of the Supply Agreement dated December 22, 2003 (the “Rite Aid Agreement”) as amended by the First Amendment to Supply Agreement dated December 8, 2007 (the “First Amendment”), the Second Amendment to the Supply Agreement dated November 7, 2008 (the “Second Amendment”), the Third Amendment to the Supply Agreement dated February 1, 2009 (the “Third Amendment”), the Fourth Amendment to the Supply Agreement dated December 11, 2009 (the “Fourth Amendment”), and the Fifth Amendment to the Supply Agreement dated June 22, 2010 (the “Fifth Amendment”) (collectively referred to herein as the “Agreement”), McKesson and Rite Aid entered into an agreement to establish a program for McKesson’s supply of pharmaceuticals and certain OTC products to Rite Aid.

 

AGREEMENT

 

For good and valuable consideration, the receipt and sufficiency of which is acknowledged, McKesson and Rite Aid agree as follows:

 

1.                                      As of the Sixth Amendment Effective Date (as defined below), Section 1.2 of the Agreement is deleted in its entirety and replaced with the following:

 

1.2.                            Renewal Term.  At the conclusion of the Initial Term this Agreement shall renew for an additional six year and five month term (“Renewal Term”) commencing on November 1, 2009 and ending on March 31, 2016, unless earlier terminated in accordance with Section 13.

 

2.                                As of the Sixth Amendment Effective Date, the following is added to Section 2.1(c) Exceptions of the Agreement:

 

xi.                                   Products purchased for dispensing by Rite Aid Specialty Pharmacy, LLC, as it currently exists or is expanded as well as any other specialty pharmacies built or acquired.

 

3.                                      As of November 1, 2012, the DSD Cost of Goods Matrix in Section 3.2 of the Agreement is deleted in its entirety and replaced with the following:

 

 

DSD COST OF GOODS MATRIX

 

	
Chain-Wide Average Product
   Purchases Per
   Location/Month (less all
   returns)
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Rite Aid
   Contract
    	
 
    	
Schedule II
    	
 
    
	
From
    	
 
    	
To
    	
 
    	
Rx
    	
 
    	
OTC
    	
 
    	
Items
    	
 
    	
Narcotics
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[**Redacted**]
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

4.                                      As of November 1, 2012, Section 3.4 of the Agreement is deleted in its entirety and replaced with the following:

 

3.4                               DSD Returns Adjustment: As an incentive for Rite Aid to continue to maintain its chain-wide average DSD return volume at or below [**Redacted**] of total DSD purchases (“DSD Acceptable Returns Volume Percentage”), Rite Aid’s DSD Cost of Goods shall only be subject to an adjustment, as determined pursuant to the matrix below, based on Rite Aid’s performance for each quarter effective for the following quarter in the event that Rite Aid does not achieve the DSD Acceptable Returns Volume Percentage. Any applicable adjustment will take place [**Redacted**] after [**Redacted**], and continue for [**Redacted**].

 

	
 
    	
% of Chain-Wide Average Saleable
   Returns & Allowances to DSD Purchases
    	
 
    	
Adjustments to Cost of Goods
   Markup on All DSD Purchases
    (Rebate Amounts Not Cumulative)
    	
 
    
	
 
    	
[**Redacted**]
    	
 
    	
[**Redacted**]
    	
 
    

 

5.                                      As of November 1, 2012, Section 3.9(a) of the Agreement is deleted in its entirety and replaced with the following:

 

(a)                                 For the period of November 1, 2012 through March 31, 2013, McKesson will issue to Rite Aid a rebate, in the form of a credit, in an amount equal to [**Redacted**] of the Cost of Goods for Warehouse purchases of Branded Rx Products and OTC Products (net of Warehouse returns as provided in Section 8.1 and excluding Warehouse Repackaged Merchandise) (the “Buy Profit Rebate”).  The Buy Profit Rebate shall be paid [**Redacted**] for purchases made [**Redacted**]. An illustration of the Buy Profit Rebate calculation is set forth below:

 

2

 

	
 
    	
Total
   [**Redacted**]
    Warehouse
    Purchases of
   Branded Rx
   Products and OTC
   Products
    	
 
    	
(-)
    Warehouse
    Returns
   (Includes
   returns to
   vendors)
    	
 
    	
(-)
    Warehouse
   Repackaged
   purchases
    	
 
    	
(X)
    Buy Profit
   Rebate of
   [**Redacted
   **]
    	
 
    	
(=)
    Buy Profit
   Rebate
    
	
 
    	
[**Redacted**]
    	
 
    	
[**Redacted**]
    	
 
    	
[**Redacted**]
    	
 
    	
[**Redacted**]
    	
 
    	
[**Redacted**]
    

 

As of April 1, 2013 through March 31, 2014 the Buy Profit Rebate will be calculated on an amount equal to [**Redacted**] (rather than the previous amount of [**Redacted**]).  From April 1, 2014 through the remainder of the Term of the Agreement, the Buy Profit Rebate shall be equal to [**Redacted**].

 

6.                                      As of the Sixth Amendment Effective Date, the third sentence of Section 3.10 of the Agreement is deleted in its entirety.

 

7.                                      As of November 1, 2012, the language “[**Redacted**]....” in Section 10.1 of the Agreement is deleted in its entirety and replaced with “[**Redacted**]” and the table immediately after Section 10.1(b) is deleted in its entirety and replaced with the following table:

 

	
 
    	
Total Annualized Rite Aid combined
   DSD and Warehouse Generic
   Purchases plus Negative Generic
   Purchasing Events(s)
    [**Redacted**] (net of any returns,
   rebates, allowances, and all credits
   and adjustments issued for Generics
   purchases).
    	
 
    	
Monthly COG adjustment or upcharge(1)
    	
 
    
	
 
    	
[**Redacted**]
    	
 
    	
[**Redacted**]
    	
 
    

 

(1)To be applied across all Cost of Goods for Products delivered by DSD, Warehouse, RxPak and Cross-Dock.

 

8.                                      As of the Sixth Amendment Effective Date, the header on the left side of the table in Section 10.1(b) of the Agreement is deleted in its entirety and replaced with the following:

 

Total Annualized Rite Aid combined DSD and Warehouse Purchases of Generics Rx Product plus Negative Generic Purchasing Event(s) [**Redacted**] (net of all returns, rebates, allowances and all credits and adjustments issued for Generics purchases).

 

9.                                      As of the Sixth Amendment Effective Date, the following is added as a new Section 10.6 to the Agreement:

 

3

 

10.6        McKesson will provide to Rite Aid [**Redacted**] reports indicating stocking levels at each McKesson Forward DC servicing Rite Aid for Generic products included in Rite Aid’s formulary.

 

10.                               As of November 1, 2012, the first paragraph of Section 11.1 of the Agreement is deleted in its entirety and replaced with the following:

 

11.1.                     In consideration of the various purchase commitments set forth in this Agreement, McKesson will provide throughout the Renewal Term of the Agreement a [**Redacted**] rebate to Rite Aid on total purchases of Merchandise (net of all returns) by Rite Aid (such rebate shall be referred to herein as a “[**Redacted**] Purchase Volume Rebate”).  Each [**Redacted**] Purchase Volume Rebate shall be paid to Rite Aid [**Redacted**].

 

11.                               This Sixth Amendment shall become effective on the first date on which both Rite Aid and McKesson shall have executed it (the “Sixth Amendment Effective Date”).

 

12.                               Except as amended above, the Agreement remains unchanged and in full force and effect.

 

13.                               This Sixth Amendment may be executed in counterparts, all of which taken together shall constitute an original.

 

14.                               This Sixth Amendment, together with the Agreement, as amended, embodies the entire agreement between the parties with regard to the subject matter hereof and supersedes all prior agreements, understandings, and representations with the exception of any promissory note, security agreement, or other credit or financial document(s) executed by Rite Aid or between Rite Aid and McKesson.

 

IN WITNESS WHEREOF, the parties have caused this Sixth Amendment to be duly executed as of the date written below.  The persons signing this Sixth Amendment warrant that they are duly authorized to sign for and on behalf of their respective parties. This Sixth Amendment shall be deemed accepted by McKesson only on its execution by a duly authorized representative of McKesson.

 

	
RITE AID CORPORATION
    	
 
    	
McKESSON   CORPORATION
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By:
    	
/s/   Christopher Hall
    	
 
    	
By:
    	
/s/   Paul C. Julian
    
	
 
    	
 
    	
 
    
	
Name:
    	
Christopher   Hall
    	
 
    	
Name:
    	
Paul   C. Julian
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
SVP,   Pharmacy Services
    	
 
    	
Title:
    	
Executive   Vice President, Group President
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
September 18,   2012
    	
 
    	
Date:
    	
October 1,   2012
    
							

 

4Exhibit 10.28

 

 

Stemline Therapeutics, Inc.

750 Lexington Avenue, 6th Floor, New York, NY 10022

www.stemline.com

 

October 1, 2012

 

PERSONAL & CONFIDENTIAL

 

Stephen Hall

32 Crows Creek Rd

Piitsboro, NC 27312

 

Dear Stephen:

 

We are delighted that you have accepted our offer to join Stemline Therapeutics, Inc. (the “Company”).  You will commence employment with the Company on October 1, 2012 (the “Start Date”).  Your employment with the Company will be on the following terms:

 

1.                                      Employment; Compensation.

 

A.                                       Title; Responsibilities.  Commencing on the Start Date, you will be employed as Vice President of Finance and Principal Financial Officer and Chief Accounting Officer of the Company, which is a full-time position.  You will report directly to the Company’s Chief Operating Officer or Vice President of Operations.  Your responsibilities shall include, without limitation, (i) accounting, (ii) internal control over financial reporting, (iii) negotiating and managing the Company’s third-party vendor contracts and (iv) human resource management.  You will be employed on an at-will basis, which means that you may resign and the Company may terminate your employment or change your job title and duties at any time for any reason or for no reason.

 

B.                                    Base Salary.  Commencing on the Start Date, your starting base salary will be $100,000 per annum, less withholdings and deductions required and/or permitted by law, payable periodically on the same schedule as other full-time employees of the Company.  Upon the consummation of the first fully underwritten, firm commitment public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended (other than on Forms S-4 or S-8 or their then equivalents), covering the offer and sale by the Company of its equity securities (the “IPO”), your base salary shall increase to $190,000 per annum, less withholdings and deductions required and/or permitted by law.  Your base salary may be adjusted from time to time by the Company’s Chief Executive Officer in his sole discretion.

 

 

C.                                    Bonuses

(a) Annual Bonus. If at the end of any calendar year you are then in the Company’s employ, you will be eligible to receive a discretionary cash bonus in an amount equal to up to 20% of your base salary then in effect (pro rated from the Start Date through December 31, 2012 for the 2012 calendar year), subject to your achievement of performance goals established by the Company’s senior management in its sole discretion, the attainment of which shall be determined by the Company’s chief executive officer in his sole discretion.

 

(b) IPO Bonus.  Upon the consummation of the first fully underwritten, firm commitment public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended (other than on Forms S-4 or S-8 or their then equivalents), covering the offer and sale by the Company of its equity securities, you shall be entitled to a cash bonus of $72,000.00 payable in two installments; (i) $36,000.00 payable at the later of the next regularly-scheduled employee payroll or the first regularly-scheduled employee payroll in 2013 and (ii) $36,000.00 payable at the first regularly-scheduled employee payroll in 2014.

 

D.                                    Options or Restricted Stock.  Subject to approval of the Company’s Board of Directors, you will be granted stock options and/or restricted stock consistent with the Company’s policy for similarly situated employees.

 

2.                                      Expense Reimbursement.  You will be entitled to reimbursement of all reasonable and properly documented business and travel expenses incurred by you in the performance of your duties hereunder, provided such expenses are approved in advance by your direct report and submitted for reimbursement in accordance with the Company’s policies.

 

3.                                      Benefits.  You will be eligible to participate in all employee benefit plans and perquisite plans and policies which the Company may, in its sole discretion, make available to its similarly situated employees, whether such benefits are now in effect or hereafter adopted, subject to the terms and conditions of each such plan or policy.  Subject to applicable law, the Company may alter, modify, add to or delete its employee benefit plans and its perquisite plans and policies at any time as it, in its sole judgment, determines to be appropriate, without recourse by you.

 

4.                                      Vacation.  You will be entitled to ten (10) days of paid vacation for each calendar year of employment (pro rated from the Start Date through December 31, 2012 for the 2012 calendar year).  Vacation may not be carried over from year to year.

 

5.                                      Inventions, Non-Competition and Non-Disclosure Agreement.  The Company has a standard Inventions, Non-Competition and Non-Disclosure Agreement, which you are required to sign as a condition of your employment and your Options grants.  I have enclosed two copies of the Inventions, Non-Competition and Non-Disclosure Agreement for your review and 

 

2

 

signature.  Please sign and return to me one copy of the Inventions, Non-Competition and Non-Disclosure Agreement and this letter.  The other copy is for your files.  Please note that to the extent any terms of the Inventions, Non-Competition and Non-Disclosure Agreement conflict with this letter, the terms of the Inventions, Non-Competition and Non-Disclosure Agreement shall govern.

 

6.                                      Verification.  Your employment is also contingent upon our receipt of proof of your identification and work authorization as required by the U.S. Immigration Reform and Control Act and, to the Company’s satisfaction, that you are not subject to any agreement or understanding that could restrict or hinder the performance of your duties as an employee of the Company.  You hereby represent that you are not subject to any agreement, understanding or other duty that would restrict or hinder the performance of your duties as an employee of the Company, including, but not limited to, any confidentiality, noncompetition or nonsolicitation agreement or understanding.

 

7.                                      Return of Company Property. You agree that upon the termination or cessation of your employment with the Company for any reason, or at any other time upon the Company’s request, you will immediately return to the Company all Company property of any kind then in your possession or under your control, including, without limitation, the originals and all copies of any and all documents, files or records (including computer data, disks, programs, or printouts) that contain any non-public information that in any way relates to the Company, any of its subsidiaries or affiliates, any of their products or services, clients, suppliers or other aspects of any of their business(es) or prospects, all other notes, drawings, lists, memoranda, magnetic disks or tapes, other recording media, reports, files, memoranda, software, credit cards, door and file keys, telephones, PDAs, computers, computer access codes, instructional manuals, and any other physical property that you received, prepared, or helped prepare in connection with your employment. You further agree to not retain any copies or excerpts of any such property in any format, whether hardcopy, electronic or otherwise.  To the extent that you have Company property stored on any home computer or other personal storage device, you agree to irretrievably delete such property after forwarding a copy of any such property to the Company.  Your obligation in this Section 5 will survive any change to your employment status with the Company, by promotion or otherwise, and the termination or cessation of your employment with the Company.

 

8.                                      Integration.  The terms and conditions of your proposed employment with the Company as set forth in this letter supersede any contrary verbal discussions concerning conditions of your employment, and this letter contains the entire understanding of the parties with regard to its subject matter.

 

9.                                      Amendment.  No amendment or other modification of this letter shall be effective unless in writing and signed by the Company and you.

 

10.                               Waiver.  Waiver by either the Company or you of a breach of any provision, term or condition hereof will not be deemed or construed as a further or continuing waiver thereof or a waiver of any breach of any other provision, term or condition of this letter.

 

3

 

11.                               Successors and Assigns.  The rights and obligations of the Company hereunder may be transferred or assigned to any successor or assign of the Company.  No assignment of this letter will be made by you, and any purported assignment will be null and void.

 

12.                               Severability.  If any arbitrator, agency, tribunal or court of competent jurisdiction finds any provision or part of this letter to be excessively broad, in whole or in part, such provision will be deemed and construed to be reduced to the maximum duration, scope or subject matter allowable under applicable law.  If any provision or part of this letter is declared illegal or unenforceable by any arbitrator, tribunal or court of competent jurisdiction even after the reformation and construction as provided in the previous sentence, then the remainder of this letter, or the application of such provision or part in circumstances other than those as to which it is so declared illegal or unenforceable, will not be affected thereby, and each provision and part of this letter will be valid and enforceable to the fullest extent permitted by law.

 

13.                               Consideration.  You agree that the provisions of this letter are reasonable and necessary for the protection of the Company.

 

14.                               Governing Law.  This letter shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to any choice of law principle that would dictate the application of the laws of another jurisdiction.

 

[Signature page follows]

 

4

 

Again, we look forward to having you join us.  If you have any questions, please feel free to call me at (646) 502-2303.

 

	
 
    	
 
    	
Very truly yours,
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
STEMLINE THERAPEUTICS, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Ivan Bergstein, M.D.
    
	
 
    	
 
    	
Name:
    	
Ivan Bergstein, M.D.
    
	
 
    	
 
    	
Title:
    	
President and Chief Executive Officer
    
	
 
    	
 
    	
 
    
	
STEPHEN HALL
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Steven Hall
    	
 
    	
 
    
	
(Signature)
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Date: October 1, 2012
    	
 
    	
 
    

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}]]